A randomized, double-blind, placebo-controlled, phase II clinical trial to investigate the efficacy and safety of oral DA-1229 in patients with type 2 diabetes mellitus who have inadequate glycaemic control with diet and exercise

@inproceedings{Jung2015ARD,
  title={A randomized, double-blind, placebo-controlled, phase II clinical trial to investigate the efficacy and safety of oral DA-1229 in patients with type 2 diabetes mellitus who have inadequate glycaemic control with diet and exercise},
  author={Chang Hee Jung and Cheol Young Park and Kyu-Joeng Ahn and N Kim and H D Jang and Moon-Kyu Lee and Joong-Yeol Park and C W Chung and Kyung-Wan Min and Y W Sung and Jeong-hyun Park and Sung Jin Kim and Hyo Jung Lee and Sung-Woo Park},
  booktitle={Diabetes/metabolism research and reviews},
  year={2015}
}
BACKGROUND DA-1229 is a novel, potent and selective dipeptidyl peptidase-4 (DPP-IV) inhibitor that is orally bioavailable. We aimed to evaluate the optimal dose, efficacy and safety of DA-1229, in Korean subjects with type 2 diabetes mellitus suboptimally controlled with diet and exercise. METHODS We enrolled 158 patients (mean age, 53 years and a mean BMI, 25.6 kg/m(2) ). The mean baseline fasting plasma glucose level, HbA1c and duration of diabetes were 8.28 mmol/L, 7.6% (60 mmol/mol) and 3… CONTINUE READING